The testing of vaccines for tuberculosis is costly and time-consuming, and dependent on preclinical animal challenge models and clinical trials. We have recently developed a mycobacterial growth inhibition assay (MGIA) to test vaccine efficacy ex vivo. This assay measures the summative effect of the host immune response and may serve as a novel tool to facilitate vaccine testing. It has generated much interest recently, and to facilitate technology transfer and reproducibility between laboratories, we here describe a detailed protocol for an ex vivo MGIA in mouse splenocytes.
Introduction
Tuberculosis (TB) is a major global health problem, and new vaccines are urgently needed. With a lack of easily measurable correlates of protection, vaccine efficacy can currently only be measured in pre-clinical animal challenge models and clinical trials, both of which are time consuming and expensive.
We have recently developed an ex vivo mycobacterial growth inhibition assay (MGIA) to facilitate vaccine testing. This assay is a refinement of protocols first described by Marsay et al. and Kolibab et al. 1, 2 Our assay provides a direct read-out of the ability of a vaccine-induced immune response to control mycobacterial growth. Its ex vivo nature requires the use of animals; however, it has the potential to be a more rapid and cost-effective pre-clinical method than those currently used, and animal welfare is improved by cutting out the need for animal challenge experiments, which are time-consuming, expensive, and require specialist containment facilities. Furthermore, the assay could be used in future as an additional read-out in clinical trials.
To facilitate and encourage technology transfer between laboratories and vaccine developers in the TB vaccine field, we here describe a protocol for an ex vivo MGIA using mouse splenocytes in sufficient detail to enable researchers to establish this assay in their own laboratories. This protocol as presented here works reliably in our hands but has not been validated across laboratories or species. We invite other researchers who are working or would like to work with this assay to discuss the method and communicate their experience via bioRxiv comments in order to further optimise it and evaluate its reproducibility.
Please note, data discussed here are unpublished at the time of deposition of this article, and this article will be updated once published data are available. A summary of key results is given where relevant.
Ex vivo MGIA Methodology

Principle
The MGIA principle is based on the notion that host cells will inhibit mycobacterial growth in cell culture ex vivo if an effective, specific immune response is induced. Using total splenocytes from mice ensures that all necessary immune cells are present in near-physiological numbers and activation stages. Co-culture of mycobacteria with these cells ex vivo allows us to measure overall change in bacterial numbers, e.g. a reduction induced by vaccination. Bacterial numbers can be quantified using a BACTEC MGIT system, which assesses bacterial growth automatically every hour. This system is based on fluorescence quenching by oxygen -the silica gel at the bottom of the tube is non-fluorescent in the presence of the oxygen-enriched mycobacterial growth medium; however when bacteria grow and their metabolism reduces oxygen concentration, fluorescence becomes more intense. Once fluorescence reaches a certain threshold, the tube is registered as positive, and the time to detection (TTD) is given. TTD is dependent on the initial number of bacteria used to inoculate the MGIT tube, and the relationship between initial bacterial numbers and TTD can be determined by producing a standard curve as described below (Fig. 1 ). The standard curve can then be used to convert TTD to bacterial numbers (CFU; colony forming units). 
Experimental design and expected outcomes
In our experience, total host cell numbers, as well as mycobacterial strain and inoculum dose, influence the difference found between vaccinated and naïve groups in this assay. We therefore recommend titrating both in a pilot experiment (Fig. 2 ).
In our hands and using the protocol described below, we found that using higher numbers of splenocytes (5x10 6 ) produced greater differences between naive and BCG-vaccinated mice, and reduced variability within groups. An input dose of ~50-100 CFU BCG Pasteur Aeras (which typically resulted in a TTD of approx. 8.5 days for the direct-to-MGIT controls) resulted in a reduction of 0.7-0.8 log10 CFU in splenocytes from vaccinated mice, a difference that was replicated in Mycobacterium tuberculosis challenge experiments. These results were obtained using C57Bl/6J mice that were immunised at the age of 6-8 weeks, and M. bovis BCG Pasteur, which was produced by the Aeras Laboratories (Rockville, MD) and is an early passage strain. We have found statistical power to be sufficient with group sizes of 6-8 animals.
★NOTE:
The TTD for the input inoculum may vary depending on the mycobacterial strain used and a standard curve should be produced for each strain. 
Procedures
The following sections give details on procedures as used in our laboratory. Standard materials (e.g. consumables such as tips or small reaction tubes) are used. Specific materials, which should not be substituted, are indicated in bold.
★NOTE:
Each laboratory must ensure they are complying with local biological safety and ethics policies and procedures. ★NOTE: Do not store MGIT tubes after the addition of PANTA enrichment. The tubes must be used the same day or discarded. 
STANDARD CURVE
Stock titration
3) Thaw one vial of the mycobacteria to be tested at room temperature.
!OPTIONAL: If the mycobacterial stock appears clumpy, it can be sonicated in a sonication water bath for 1 min. Place vial on ice for 1 min and repeat.
★NOTE:
The homogeneity of the mycobacterial stock has an impact on the reproducibility of the results in this assay. It is important that the input dose is reproducible between experiments. Sonication might help to achieve this. If the stock preparation is homogenous and input doses are consistent without sonication, this step can be omitted. ★NOTE: Record tube numbers (given on barcode) or position within the drawer for each samplethis will make it easier to identify samples from the MGIT report ( Fig. 3 ). 9) Divide two 7H11 agar plates into 3-4 sectors each. Spot 3x20 µl from each dilution onto a section. Leave plates to dry. Seal plates in sealable bags or with Parafilm to prevent drying out. Place in incubator at 37°C. Count colonies as soon as they are visible (after 3-4 weeks for most standard BCG strains; colonies of BCG Pasteur from Aeras are countable after approx. 10-12 days). Counts from spots should be approx. between 4 and 30 colonies.
10) Calculate standard curve by plotting TTD against input CFU as determined by plating or the equivalent volume (step 9) and use regression analysis to obtain the equation that can be used to convert any TTD to volume or CFU ( Fig. 1 ; also see data analysis section). 13) Carry out the ex vivo MGIA as described below at the time point of the peak immune response after immunisation.
Our data were obtained at 6 weeks after the immunisation with BCG Pasteur Aeras in C57Bl/6J mice. However, the ex vivo MGIA should be carried out at the time point of the peak immune response, which is depending on vaccine candidate and mouse strain used.
EX VIVO MGIA
Materials (all sterile except ice):
• Ice ★NOTE: As cells will be co-cultured with bacteria, cells must be processed and cultured in antibiotic-free medium. Strict sterile working technique must be observed to avoid contamination.
13) Dissect spleens from mice aseptically, place in 5 ml sterile RPMI-MGIT medium in a 50 ml Falcon tube.
14)
Pour spleen and 5 ml RPMI-MGIT into a cell strainer in a small petri dish.
15) Mash spleen through strainer by applying gentle pressure using the rubber end of a plunger from a 5 ml syringe.
16) Transfer cells back to 50 ml Falcon using a disposable pastette. 17) Centrifuge cells at approx. 450g for 5 min at 4°C. ★NOTE: These two duplicate tubes are the "direct-to-MGIT" positive controls. They serve as quality control to ensure reproducibility of input inocula, and can also be used to normalise data across experiments (see data analysis section).
!OPTIONAL: If using a live vaccine such as BCG, it may be desirable to set up control MGIT tubes to detect any residual BCG from the immunisation by adding 5 million cells in 300 μl (from previously prepared cell suspension) from each mouse to a supplemented MGIT tube. Add 200 μl RPMI-MGIT to make the total volume added to the tube 500 μl. 
DATA ANALYSIS
The previously prepared standard curve (Fig. 1 ) allows for conversion of the TTD given on the MGIT report (see Fig. 3 below for an example) to CFU. GraphPad Prism software works well for regression analysis and determining the equation that describes the relationship between the initial CFU input and TTD. Microsoft Excel provides a similar functionality, but we found Prism to provide more options.
★NOTE: Depending on whether CFU or log10 converted CFU values are used in the standard curve, the regression analysis is slightly different. Log10 CFU as shown in the example in Fig. 1 can be fitted with a linear regression, whilst using CFU requires the fitting of a semi-log line.
The regression analysis will provide you with a R 2 value (a measure of how well the line fits the data), and the equation describing the line. Solve the equation for X: Y= A*X + B -> X = (Y-B)/A (where A = slope; B = intersect). By inserting the TTD (=Y), the number of CFU (or log10 CFU) initially added to the tube can now be calculated.
★NOTE:
It is important to distinguish between total CFU and CFU/ml, as the TTD will indicate total numbers of bacteria per MGIT tube (i.e. in this assay, the number of bacteria in each MGIA sample (steps 30 & 31) of originally 600 μl).
This data can now be plotted in a graph as is best suited for the experiment. If desirable, log10 CFU can be converted to CFU and vice versa. If more than one experiment is to be compared, it may be advisable to normalise data to the direct-to-MGIT controls to account for differences in input inocula. In this case, the number of total CFU per sample would be divided by the number of total CFU in the direct-to-MGIT control to give a read-out of relative growth, or fold-change in bacterial number. This can be up to 56 days. Start of protocol: the date and time the sample is registered in the instrument; this field will be empty until the first reading is taken.
Discussion
At a time when STOP TB and the WHO have called for an ambitious goal to end TB as a global epidemic by 2035 (an average less than 10 tuberculosis cases per 100,000 population; cut the number of deaths from TB by 95%), funding to achieve this goal grows more scarce and it is now more important than ever for scientists within the TB community (and other fields) to join forces, use the available budgets strategically, and to seek new avenues for vaccine testing and development. This is reflected by the encouragement of funding bodies to form large research consortia such as TBVAC2020 and EMI-TB. In an effort to facilitate technology transfer and help standardise vaccine testing, between and within these groups, we describe here a detailed protocol for an ex vivo Mycobacterial Growth Inhibition Assay (MGIA) which offers an alternative approach to currently used cytokine-based assays for the assessment of new TB vaccine candidates. 3, 4 These assays measure directly the summative ability of host cells to control mycobacterial growth, a more holistic assessment criterion for novel vaccine candidates than the in vitro assays currently used. These assays also provide a unique opportunity to manipulate the host response in a very defined manner and measure the effect on the ability to control bacterial growth, e.g. by neutralisation of cytokines, depletion of specific host cell populations, or use of genetically modified strains of both animals or mycobacteria. Although similar assays have been described 1,2,5,6 , they have not been widely adopted by TB vaccine developers as they have been perceived as difficult to establish and lacking in reproducibility. This manuscript provides detailed descriptions of both laboratory methods and data analysis for a pre-clinical ex vivo MGIA method first described by Marsay et al. We aim to facilitate the uptake of this assay by TB vaccine developers. We detail the critical considerations for establishment of this assay and provide an assay optimisation strategy for transfer of the assay into a new laboratory and assessment of a new mycobacterial infection stock.
For this assay to be a useful tool for vaccine assessment in humans, blood is the only feasible sample to use, and a PBMC-based, as well as a whole blood assay are currently under development. 7, 8 It may be possible to determine bacterial numbers at the end of the 4 day incubation period by conventional plating of the lysed cells on 7H11 agar plates; however, we have not yet tested this approach. It would make these experiments more cost effective, and independent of the availability of a BACTEC MGIT system. On the other hand, the BACTEC MGIT system provides a wide dynamic range and sensitivity in the determination of the bacterial load that is not matched by culture on solid media, where several dilutions of one sample may have to be plated.
All in all we believe that this assay will be of use for many groups within the TB research community, and will contribute to the development of an effective vaccine against tuberculosis.
